Plus Therapeutics CNSide assay gains Medical Mutual coverage in Ohio

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), announced a regional coverage agreement with Medical Mutual, effective July 1, 2026, covering approximately 1.2 million members in Ohio and Kentucky for the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay.

The agreement brings the total contracted coverage for the CNSide assay to approximately 127 million people, according to a company statement.

The CNSide® assay is designed to support diagnosis, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The company reports that more than 11,000 tests have been performed at over 120 U.S. cancer institutions since 2020, with the assay showing 92% sensitivity and 95% specificity, and influencing treatment decisions in 90% of cases.

The test is available exclusively through CNSide Diagnostics, LLC as a laboratory-developed testing service for health care professionals in the U.S.

Plus Therapeutics also announced it will change its corporate name to Cerenome, Inc. and begin trading on Nasdaq under the ticker symbol CNSY, effective August 3, 2026. Until that date, the company will continue to operate as Plus Therapeutics under the ticker symbol PSTV.

You May Also Be Interested In

• Waymo Explores Split With Uber - FT
• Paramount Skydance extends bond offer deadlines to August 7
• Elme Communities cuts liquidating distribution estimate after Riverside deal